Genetically engineered mouse model of pleomorphic liposarcoma: Immunophenotyping and histologic characterization
CONCLUSION: Genetically engineered RPP mice reliably produced soft-tissue tumors consistent with pleomorphic liposarcoma, which immunological findings similar to other soft-tissue sarcomas. This model may demonstrate utility in testing treatments for this rare disease, including immunomodulatory therapies.PMID:38199172 | PMC:PMC10788790 | DOI:10.1016/j.neo.2023.100956 (Source: Neoplasia)
Source: Neoplasia - January 10, 2024 Category: Cancer & Oncology Authors: Jeffrey Mark Brown Rahi Patel Kyllie Smith-Fry Michael Ward Trudy Oliver Kevin B Jones Source Type: research
Cardiac substructures dosimetric predicts cardiac toxicity and prognosis in esophageal squamous cell cancer treated by radiotherapy
CONCLUSIONS: In the population of ESCC patients receiving RT, we showed that the CS factors had a substantial predictive value for the various types and grades of CEs. The elevated radiation dose of LAD was a significant contributor to a higher rate of cardiac events and a worse prognosis.PMID:38199173 | PMC:PMC10788793 | DOI:10.1016/j.neo.2024.100969 (Source: Neoplasia)
Source: Neoplasia - January 10, 2024 Category: Cancer & Oncology Authors: Zhicheng Jin Xuefeng Sun Chao Zhou Haihua Yang Suna Zhou Source Type: research
Lactate promoted cisplatin resistance in NSCLC by modulating the m6A modification-mediated FOXO3/MAGI1-IT1/miR-664b-3p/IL-6R axis
CONCLUSION: Lactate promoted NSCLC cisplatin resistance through regulating FOXO3/MAGI1-IT1/miR-664b-3p/IL6R axis in YTHDF2-mediated m6A modification.PMID:38184887 | PMC:PMC10808932 | DOI:10.1016/j.neo.2023.100960 (Source: Neoplasia)
Source: Neoplasia - January 7, 2024 Category: Cancer & Oncology Authors: Wei Bo Ning Yu Xiaokai Wang Chun Wang Chunying Liu Source Type: research
Lactate promoted cisplatin resistance in NSCLC by modulating the m6A modification-mediated FOXO3/MAGI1-IT1/miR-664b-3p/IL-6R axis
CONCLUSION: Lactate promoted NSCLC cisplatin resistance through regulating FOXO3/MAGI1-IT1/miR-664b-3p/IL6R axis in YTHDF2-mediated m6A modification.PMID:38184887 | DOI:10.1016/j.neo.2023.100960 (Source: Neoplasia)
Source: Neoplasia - January 7, 2024 Category: Cancer & Oncology Authors: Wei Bo Ning Yu Xiaokai Wang Chun Wang Chunying Liu Source Type: research
Genomic profiling in GIST: Implications in clinical outcome and future challenges
Neoplasia. 2024 Jan 5;48:100959. doi: 10.1016/j.neo.2023.100959. Online ahead of print.ABSTRACTGastrointestinal Stromal Tumors (GIST) are the most frequent mesenchymal neoplasia of the digestive tract. Genomic alterations in KIT, PDFGRA, SDH, and BRAF genes are essential in GIST oncogenesis. Therefore, the mutations in these genes have demonstrated clinical implications. Tumors with deletions in KIT-exon 11 or duplications in exon 9 are associated with a worse prognosis. In contrast, KIT-exon 11 substitutions and duplications are associated with a better clinical outcome. Moreover, mutations in Kit exon 9 and 11 are action...
Source: Neoplasia - January 6, 2024 Category: Cancer & Oncology Authors: German Calderillo-Ru íz Eloy Andr és Pérez-Yepez Mar ía Alejandra García-Gámez Oliver Millan-Catalan Consuelo D íaz-Romero Paul Ugalde-Silva Rodrigo Salas-Benavides Carlos P érez-Plasencia Berenice Carbajal-L ópez Source Type: research
Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents
Neoplasia. 2024 Jan 5;48:100962. doi: 10.1016/j.neo.2023.100962. Online ahead of print.ABSTRACTBispecific agents are a rapidly growing class of cancer therapeutics, and immune targeted bispecific agents have the potential to expand functionality well beyond monoclonal antibody agents. Humabodies⁎ are fully human single domain antibodies that can be linked in a modular fashion to form multispecific therapeutics. However, the effect of heterogeneous delivery on the efficacy of crosslinking bispecific agents is currently unclear. In this work, we utilize a PSMA-CD137 Humabody with an albumin binding half-life extension (HLE...
Source: Neoplasia - January 6, 2024 Category: Cancer & Oncology Authors: Anna Kopp Hyeyoung Kwon Colette Johnston Steven Vance James Legg Laurie Galson-Holt Greg M Thurber Source Type: research
Genomic profiling in GIST: Implications in clinical outcome and future challenges
Neoplasia. 2024 Jan 5;48:100959. doi: 10.1016/j.neo.2023.100959. Online ahead of print.ABSTRACTGastrointestinal Stromal Tumors (GIST) are the most frequent mesenchymal neoplasia of the digestive tract. Genomic alterations in KIT, PDFGRA, SDH, and BRAF genes are essential in GIST oncogenesis. Therefore, the mutations in these genes have demonstrated clinical implications. Tumors with deletions in KIT-exon 11 or duplications in exon 9 are associated with a worse prognosis. In contrast, KIT-exon 11 substitutions and duplications are associated with a better clinical outcome. Moreover, mutations in Kit exon 9 and 11 are action...
Source: Neoplasia - January 6, 2024 Category: Cancer & Oncology Authors: German Calderillo-Ru íz Eloy Andr és Pérez-Yepez Mar ía Alejandra García-Gámez Oliver Millan-Catalan Consuelo D íaz-Romero Paul Ugalde-Silva Rodrigo Salas-Benavides Carlos P érez-Plasencia Berenice Carbajal-L ópez Source Type: research
Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents
Neoplasia. 2024 Jan 5;48:100962. doi: 10.1016/j.neo.2023.100962. Online ahead of print.ABSTRACTBispecific agents are a rapidly growing class of cancer therapeutics, and immune targeted bispecific agents have the potential to expand functionality well beyond monoclonal antibody agents. Humabodies⁎ are fully human single domain antibodies that can be linked in a modular fashion to form multispecific therapeutics. However, the effect of heterogeneous delivery on the efficacy of crosslinking bispecific agents is currently unclear. In this work, we utilize a PSMA-CD137 Humabody with an albumin binding half-life extension (HLE...
Source: Neoplasia - January 6, 2024 Category: Cancer & Oncology Authors: Anna Kopp Hyeyoung Kwon Colette Johnston Steven Vance James Legg Laurie Galson-Holt Greg M Thurber Source Type: research
Hsa_circ_0001583 fuels bladder cancer metastasis by promoting staphylococcal nuclease and tudor domain containing 1-mediated MicroRNA decay
This study adds hsa_circ_0001583 to the pool of bladder cancer metastasis biomarkers and therapeutic targets.PMID:38176295 | DOI:10.1016/j.neo.2023.100963 (Source: Neoplasia)
Source: Neoplasia - January 4, 2024 Category: Cancer & Oncology Authors: Chunyu Liu Yukun Cong Liang Chen Fang Lv Lulin Cheng Yarong Song Yifei Xing Source Type: research
Hsa_circ_0001583 fuels bladder cancer metastasis by promoting staphylococcal nuclease and tudor domain containing 1-mediated MicroRNA decay
This study adds hsa_circ_0001583 to the pool of bladder cancer metastasis biomarkers and therapeutic targets.PMID:38176295 | DOI:10.1016/j.neo.2023.100963 (Source: Neoplasia)
Source: Neoplasia - January 4, 2024 Category: Cancer & Oncology Authors: Chunyu Liu Yukun Cong Liang Chen Fang Lv Lulin Cheng Yarong Song Yifei Xing Source Type: research
Hsa_circ_0001583 fuels bladder cancer metastasis by promoting staphylococcal nuclease and tudor domain containing 1-mediated MicroRNA decay
This study adds hsa_circ_0001583 to the pool of bladder cancer metastasis biomarkers and therapeutic targets.PMID:38176295 | DOI:10.1016/j.neo.2023.100963 (Source: Neoplasia)
Source: Neoplasia - January 4, 2024 Category: Cancer & Oncology Authors: Chunyu Liu Yukun Cong Liang Chen Fang Lv Lulin Cheng Yarong Song Yifei Xing Source Type: research
Secreted insulin-like growth factor binding protein 5 functions as a tumor suppressor and chemosensitizer through inhibiting insulin-like growth factor 1 receptor/protein kinase B pathway in acute myeloid leukemia
CONCLUSIONS: Our findings revealed secreted rather than intracellular IGFBP5 as a tumor-suppressor and chemosensitizer in AML. Upregulation of serum IGFBP5 by overexpression or addition of extrinsic rhIGFBP5 may serve as a suitable therapeutic approach for AML.PMID:38159363 | DOI:10.1016/j.neo.2023.100952 (Source: Neoplasia)
Source: Neoplasia - December 30, 2023 Category: Cancer & Oncology Authors: Beiying Zhang Xiaoling Deng Ruolan You Jingru Liu Diyu Hou Xiaoting Wang Shucheng Chen Dongliang Li Qiang Fu Jingdong Zhang Huifang Huang Xiaoli Chen Source Type: research
Secreted insulin-like growth factor binding protein 5 functions as a tumor suppressor and chemosensitizer through inhibiting insulin-like growth factor 1 receptor/protein kinase B pathway in acute myeloid leukemia
CONCLUSIONS: Our findings revealed secreted rather than intracellular IGFBP5 as a tumor-suppressor and chemosensitizer in AML. Upregulation of serum IGFBP5 by overexpression or addition of extrinsic rhIGFBP5 may serve as a suitable therapeutic approach for AML.PMID:38159363 | DOI:10.1016/j.neo.2023.100952 (Source: Neoplasia)
Source: Neoplasia - December 30, 2023 Category: Cancer & Oncology Authors: Beiying Zhang Xiaoling Deng Ruolan You Jingru Liu Diyu Hou Xiaoting Wang Shucheng Chen Dongliang Li Qiang Fu Jingdong Zhang Huifang Huang Xiaoli Chen Source Type: research
Advanced progress of spatial metabolomics in head and neck cancer research
This article comprehensively reviews the progress of spatial metabolomics in head and neck cancer research, encompassing insights into cancer cell metabolic reprogramming. Various mass spectrometry imaging techniques, such as secondary ion mass spectrometry, stroma-assisted laser desorption/ionization, and desorption electrospray ionization, enable in situ metabolite analysis for head and neck cancer. Finally, significant emphasis is placed on the application of presently available techniques for early diagnosis, margin assessment, and prognosis of head and neck cancer.PMID:38142528 | DOI:10.1016/j.neo.2023.100958 (Source: Neoplasia)
Source: Neoplasia - December 24, 2023 Category: Cancer & Oncology Authors: Huiting Zhao Chaowen Shi Wei Han Guanfa Luo Yumeng Huang Yujuan Fu Wen Lu Qingang Hu Zhengjun Shang Xihu Yang Source Type: research
Characteristics and survival of primary urothelial carcinoma of the prostate: A multi-center retrospective study of 18 cases
CONCLUSION: PUCP, a rare but highly aggressive type of prostate cancer, should be considered in men with abnormalities on MRI and normal serum PSA concentrations. Positive GATA-3, P63, and negative PSA are typical immunohistochemistry features. Radical cystectomy and systematic therapies can be effective.PMID:38142529 | DOI:10.1016/j.neo.2023.100961 (Source: Neoplasia)
Source: Neoplasia - December 24, 2023 Category: Cancer & Oncology Authors: Junjie Ji Tian Liu Yu Yao Wen Liu Hao Ning Tongyu Wang Guiming Zhang Source Type: research
